Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: Superior prostate-specific antigen response compared with external beam treatment

Cancer Journal from Scientific American

Volumn 3, Issue 6, 1997, Pages 346-352

  Stromberg, Jannifer S ^a   Martinez, Alvaro A ^a   Horwitz, Eric M ^a   Gustafson, Gary S ^a   Gonzalez, Jose A ^a   Spencer, William E ^a   Brabbins, Donald S ^a   Dmuchowski, Carl F ^a   Hollander, Jay B ^a   Vicini, Frank A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Antigens neoplasm; Brachytherapy; Iridium radioisotope; Prostatic neoplasms

Indexed keywords

IRIDIUM 192; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IRIDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0031454233     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Partin A, Pound C, Clemens J et al. Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol Clin North Am 1993;20:713-725.
2. D'Amico A, Whittington R, Malkowicz S et al. A multivariate analysis of dinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995;154:131-138.
3. Zietman A, Edelstein R, Coen J et al. Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 1994;43:828-833.
4. Zietman A, Coen J, Shipley W et al. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostatic specific antigen value as a predictor of outcome. J Urol 1994;151: 640-645.
5. Kaplan I, Cox R, Bagshaw M. Prostate specific antigen after external beam radiotherapy for prostatic cancer: follow-up. J Urol 1993; 149:519-522.
6. Lee W, Hanks G, Schultheiss T et al. Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen-driven outcome analysis. J Clin Oncol 1995;13:464-469.
7. Kuban D, El-Mahdi A, Schellhammer P. Prostate-specific antigen for pretreatment prediction and post treatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:307-316.
8. Horwitz E, Vicini F, Ziaja E et al. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys 1996;36:565-571.
9. Zagars G, Pollack A, von Eschenbach A Prostate cancer and radiation therapy - the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995;33:23-35.
10. Pilepich M, Krall J, Al-Sarraf M et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616-623.
11. Bolla M, Gonzalez D, Warde P et al. Controlled clinical trial in high metastatic risk carcinoma of the prostate comparing pelvic radiotherapy alone to pelvic radiotherapy plus LHRH analogue. Int J Radiat Oncol Biol Phys 1996;36[suppl 1]:227.
12. Pilepich M, Caplan R, Byhardt R et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Onoclogy Group protocol 85-31. J Clin Oncol 1997; 15:1013-1021.
13. Hanks G, Lee W, Hanlon A et al. Conformal technique boost escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pre-treatment prostate specific antigen ≥ 10 ng/mL. Int J Radiat Oncol Biol Phys 1996;35:861-868.
14. Sandler H, McLaughlin P, Kish K et al. Results of 3D conformal radiotherapy in the treatment of 707 patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:141.
15. Leibel S, Zelefsky M, Kutcher G et al. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a phase 1 dose-escalation study. J Urol 1994;152: 1792-1798.
16. Gustafson G, Martinez A, Edmundson G et al. Overcoming internal prostate motion and set-up inaccuracies with conformal interstitial brachytherapy. Int J Radiat Oncol Biol Phys 1995;32 [suppl 1]:199.
17. Edmundson G, Rizzo N, Teahan M et al. Concurrent treatment planning for outpatient high dose rate prostate template implants. Int J Radiat Oncol Biol Phys 1993;27:1215-1223.
18. Stromberg J, Martinez A, Gonzalez J et al. Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 1995;33:161-171.
19. Martinez A, Gonzalez J, Stromberg J et al. Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial. Int J Radiat Oncol Biol Phys 1991;33:1019-1027.
20. American Joint Committee on Cancer: Manual for Staging of Cancer (4th ed). Philadelphia: Lippincott, 1992.
21. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958; 53:457-481.
22. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22: 719-748.
23. Altman D: Practical Statistics for Medical Research. London: Chapman & Hall, 1991:179-268.
24. Cox D. Regression models and life tables. Journal of the Royal Statistical Society 1972;B34:187-220.
25. Mate T, Gottesman J. Fractionated HDR conformal prostate brachytherapy. Proceedings of the 8th International Brachytherapy Conference; Nov. 25-28, 1995; Nice, France.
26. Beard C, Kijewski P, Bussiere M et al. Analysis of prostate and seminal vesicle motion: implications for treatment planning. Int J Radiat Oncol Biol Phys 1996;34:451-458.
27. Melian E, Kutcher G, Leibel S et al. Variation in prostate position: quantitation and implications for three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1993;27[suppl 1]:137.
28. Soffen E, Hanks G, Hwang C et al. Conformal static field therapy for low volume low grade prostate cancer with rigid immobilization. Int J Radiat Oncol Biol Phys 1991;20:141-146.
29. Roach M, Pickett B, Rosenthal S et al. Defining treatment margins for six field conformal irradiation of localized prostate cancer. Int J Radiat Oncol Biol Phys 1993;28:267-275.
30. Hall E: Radiobiology for the Radiologist. Philadelphia: Lippincott, 1994:117-118.
31. Partin A, Yoo J, Carter H. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-114.
32. Asbell S, Krall J, Pilepich M et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 1988;15:1307-1316.
33. McGowan D. The value of extended field radiation therapy in carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1981;7: 1333-1339.
34. Bagshaw M. Potential for radiotherapy alone in prostatic cancer. Cancer 1985;55:2079-2085.
35. Hanks G, Lee W, Hanlon A et al. Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥ 10 ng/mL. Int J Radiat Oncol Biol Phys 1996;35:861-868.
36. Roach M, Meehan S, Kroll S et al. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J Urol 1996; 156:1719-1723.